Getting to Complete Response With Less Toxicity in HER2-Positive Early Breast Cancer
3 Articles
3 Articles
Getting to Complete Response With Less Toxicity in HER2-Positive Early Breast Cancer
(MedPage Today) -- In the DESTINY-Breast11 (DB11) trial, trastuzumab deruxtecan (T-DXd, Enhertu), followed by the taxane paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta) in combination (THP), improved pathologic complete response...
Targeted Nanozyme Therapy For HER2 Cancer - Data Intelligence
Researchers have developed a new nanomaterial platform that combines nanozymes with antibody targeting to improve the precision and effectiveness of treatment in HER2-positive cancer models. Their goal is to block transcriptional processes that support tumor growth and spread by disrupting gene expression pathways central to cancer progression. Image Credit: alicancomertpay/Shutterstock.com Background HER2 (human epidermal growth factor receptor…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium